PH26596A - Modification of the DNA sequence between the shine-dalgarno sequence and the start codon of the TRP operon to increase protein expression - Google Patents
Modification of the DNA sequence between the shine-dalgarno sequence and the start codon of the TRP operon to increase protein expression Download PDFInfo
- Publication number
- PH26596A PH26596A PH33672A PH33672A PH26596A PH 26596 A PH26596 A PH 26596A PH 33672 A PH33672 A PH 33672A PH 33672 A PH33672 A PH 33672A PH 26596 A PH26596 A PH 26596A
- Authority
- PH
- Philippines
- Prior art keywords
- sequence
- dna
- coli
- start codon
- vector
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 37
- 108091081024 Start codon Proteins 0.000 title claims abstract description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 title description 9
- 230000004048 modification Effects 0.000 title description 5
- 238000012986 modification Methods 0.000 title description 5
- 108020004414 DNA Proteins 0.000 claims abstract description 32
- 241000588724 Escherichia coli Species 0.000 claims abstract description 26
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 23
- 230000007017 scission Effects 0.000 claims abstract description 23
- 239000002773 nucleotide Substances 0.000 claims abstract description 16
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 16
- 239000013598 vector Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 108091033380 Coding strand Proteins 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000007515 enzymatic degradation Effects 0.000 claims abstract description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 5
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 claims abstract description 4
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 3
- 238000011049 filling Methods 0.000 claims abstract description 3
- 230000000295 complement effect Effects 0.000 claims abstract 2
- 239000013612 plasmid Substances 0.000 claims description 34
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 8
- 229960000723 ampicillin Drugs 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 2
- 229940029575 guanosine Drugs 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 238000011534 incubation Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Electrotherapy Devices (AREA)
- Complex Calculations (AREA)
- Advance Control (AREA)
Abstract
For the contracting states : BE, CH, DE, GB, IT, LI, LU, NL, SE 1. DNA segment of the trp operon from E. coli, characterized by the sequence (coding strand) I 5' CTATCGACC 3' (I) which is connected at the 5' end to the Shine-Dalgarno sequence AAGG, and at the 3' end to the start codon ATG. For the contracting state : AT 1. A process for the preparation of a vector having the trp expression system of E. coli, characterized by cleavage with the restriction enzyme Nco l of an E. coli vector which contains the DNA sequence I 5' GTATCGACC 3' (I) (coding strand) followed by 5' ATGG 3', and a) ligation of a gene structure of DNA sequence II 5' CATG X... 3' 3' Y... 5' (II) in which X and Y denote the first complementary pair of nucleotides downstream of the start codon of a structural gene, in the cleavage site, or b) enzymatic filling in of the cleavage site and ligation of the DNA of the sequence III 5' GTA TCG ACC ATG 3' (III) 3' CAT AGC TGG TAC 5' with a DNA of the sequence IV 5' X... 3' (IV) 3' Y... 5' in which X and Y have the abovementioned meaning, or c) enzymatic degradation of the protruding sequence of the cleavage site, and ligation of the DNA of the sequence VI 5' GTA TCG AC 3' (VI) 3' CAT AGC TG 5' with a DNA of the sequence VII 5' Z ATG X... 3' (VII) 3' Z'TAC Y... 5' Z and Z' denoting any desired pair of nucleotides, which can also be dispensed with.
Description
{ “QO ' ' | [
LN ' to 26596
HOECHST AKTIENGESELLSCHAFT HOE 85/F 072 Dr.KL/mi (J Modification of the DNA sequence between the Shine-
Dalgarno sequence and the start codon of the trp operon to increase protein expression
Regulation sequences of the trp operon are frequently used for the expression of eukaryotic proteins in E. coli.
A DNA segment containing the promoter and the operator of the trp operon is now commercially available.
Modifications of the regulation sequences of the trp operon have already been disclosed. Thus, the possibility of the incorporation of a Hind 111 cleavage site between the ribosomal binding site and the start codon in the nucleotide sequence of the regulation element of the trp operon from Serratia marcescens, for example, is described in German Offenlegungsschrift 3,247,922 (corresponding to
South African Patent No. 83/9519 and Published Australian
Patent Application No. 83/22832). The insertion of a Cla I cleavage site into the corresponding sequence of E. coli is disclosed in J.C. Edman et al., Nature 291 (1981) 503- 506. However, this modification alters the number of nucleotides between the ribosomal binding site and the start codon compared with the natural sequence.
It has now been found that a cleavage site for a restric- tion enzyme can be inserted in the DNA sequence between the ribosomal binding site and the start codon by replacement of a single nucleotide, that is to say with- out altering the number of nucleotides. According to the invention, the nucleoside adenosine which is located immediately upstream of the start codon is replaced by cytidine.
The invention thus relates to a modified DNA segment of the trp operon of E. coli, which is located between the
( v | . . ~~ to a] —- 2 -—
Shine-Dalgarno sequence and the first start codon and has “. J the DNA sequence 1 5' GTATCGACC 3 (1) 3' CATAGCTGG 5°
This sequence I is connected at the 5' end of the upper strand to the Shine-Dalgarno sequence 5' AAGG 3 3' TTCC 5°! of the trp operon (which, at the level of the RNA, corres- ponds to the actual ribosomal binding site), and is connected at the 3' end of the upper strand to the start codon ATG. - The sequence I according to the invention is compared below with the natural E. coli sequence and the sequence disclosed by Edman et al., op. cit., only the upper strand, called the "coding strand" below, being shown for reasons of clarity:
SL : E. coli GTA TCG ACA
Edman et al. GTA TCG AT
Sequence 1 GTA TCG ACC (Alterations from the E. coli sequence are underlined.) : 30 This replacement according to the invention of the A in the natural sequence by C entails the following advan- i tages:
If the nucleoside guanosine is connected downstream of the start codon ATG then the recognition sequence
CLCATGG
TU re het pre nes sey ye ee at pe Pry owt tor «edi pag th tome
! ’ Cy C , — 3 -— for the restriction enzyme Nco I is formed. This cleavage : site permits the insertion of DNA in the immediate neigh- ) bourhood of the start codon, for example by use of synthetic oligonucleotides of the formula 11 5! CATGX... 3! (11) 3! Y... 5°! in which X and Y denote the first complementary nucleo- tide pair downstream of the start codon of a structural gene. If in this formula X represents G, and Y represents
C, then the Nco I cleavage site is retained in the liga- tion product. If, in contrast, for example a synthetic linker is inserted, whose protruding sequence 5' CATG 3', is connected to another nucleotide, then, although the
Nco I cleavage site is eliminated, on the other hand there is complete variability with regard to the first amino acid downstream of the start codon.
Of course, it is also possible to fill in enzymatically the protruding ends of the DNA which has been cut with
Nco 1, for example using Klenow polymerase, and to ligate the blunt-ended DNA of the sequence 111, which has thus been obtained, 5! GTA TCG ACC ATG 3 (111) : 3 CAT AGC TGG TAC 5° with a blunt-ended sequence 1V 5° X ... 3 (1v) 3 Y ... 5! to give the DNA sequence V 5! GTA TCG ACC ATG X ... 3 (v) 3 CAT AGC TGG TAC Y ... 5!
. a Co tot . - 4 -
X and Y having the abovementioned meanings. No further start codon for a particular structural gene which is to be expressed is required in this. This is favorable for the preparation of proteins shortened at the N-terminal end, for example. : Another possibility is enzymatic degradation of the pro- } truding ends, this likewise resulting in a blunt-ended
DNA sequence VI 5' GTA TCG AC 3! (v1) 3 CAT AGC TG 5' which can be ligated with a blunt-ended sequence VII 5! Z ATG X ... 3! (Vil) 3! I'TAC Y ... 5! . . to give the DNA sequence VIII | Co - 50 GTA TCG ACZ ATG X ... 3 | (VIII)
So 3 CAT AGC TGZ'TAC Y ... 50
Z and 7' denoting any desired nucleotide pair, which can
Co 25 also be dispensed with. The natural E. coli sequence is formed when Z and Z' represent A and T respectively. :
Apart from these diverse cloning possibilities, the in- vention offers the advantage that the expression of the : 30 structural gene is improved to a surprising extent.
Another aspect of the invention relates to a process for the preparation of a vector containing the trp expression
Co system from E. coli, which comprises cleavage of an E. coli vector which contains the DNA sequence 1 (coding strand) followed by 5' ATGG 3' with the restriction en- zyme Nco I and
Cy et GE
: ‘ Co Co - 5 - a) ligation of a gene structure of DNA sequence Il into the cleavage site or b) enzymatic filling in of the cleavage site and lig- ation of the DNA of the sequence IIl1 with a DNA of the sequence IV or ¢) enzymatic degradation of the protruding sequence of the cleavage site and Ligation of the DNA of the sequence VI with the DNA of the sequence VII.
Another aspect of the invention relates to E. coli host organisms which contain a vector obtained according to the invention. Furthermore, the invention relates to 2a process for the preparation of polypeptides composed of genetically codable amino acids, which comprises induc- tion, in a known manner, of expression by E. coli cells which have been transformed with a vector according to
EE the invention. oo
Further aspects of the invention, and their preferred embodiments, are illustrated in detail below and set out in the patent claims.
Figures 1 to 3 illustrate the exemplary embodiments in detail. Thus, Figure 1 shows the preparation of the plasmid pH 131/5 from the known plasmid ptrpL 1. Figure 2 shows the preparation of the plasmid pH 185/11, which codes for interleukin-2, from the known plasmid p 159/6 and the plasmid pH 131/5 (Figure 1). Finally, Figure 3 shows the plasmid pH 192/5 which codes for B-interferon.
A particular embodiment of the invention comprises the vector having ampicillin resistance with the A-lLactamase promoter in the same orientation as the trp promoter.
This is because it has emerged, surprisingly, that, owing to the trp operon modified according to the invention, there is not only very pronounced expression of the gene located downstream of the start codon but also the pos- sibility of induction of the B-lactamase. An increased ec 26596 concentration of g-lLactamase confers resistance to relatively high concentrations of ampicillin, by which means another possibility of selection is opened up.
This makes it possible rapidly to test particularly favo- rable promoter mutations or modifications of the nucleo- tides in the region of the ribosomal binding site for each protein which is to be expressed.
If the simultaneous formation of A-lLactamase is un- desired, but the intention is to make use of vectors having ampicillin resistance, it can be suppressed by insertion of a terminator between the structural gene for the desired polypeptide and the structural gene for B- lactamase. Another embodiment of this aspect of the in- vention accordingly comprises the insertion of a suitable terminator, preferably a bacterial terminator, between the abovementioned genes. The terminator of the trp ope- ron is particularly suitable, which is incorporated at a suitable site, for example 10 to 20 nucleotides down- stream of the stop codon (or the stop codons) for the : . Structural gene, or immediately upstream of the g. lactamase operon. oo -
The gene construct having the trp promoter/operator according to the invention can be incorporated in all plasmids replicating in E. coli. It is advantageous to use the commercially available E. coli vectors, such as
PBR 322, pBR 325, pACYC 177, pACYC 184 and pUC 8, and their derivatives. Examples of suitable derivatives are - 30 those plasmids from which the non-essential regions have been removed, cleavage sites or markers have been intro- duced or have been modified.
The gene sequences II, IV, V, VII and Vill contdin, with the nucleotide pair XY, the start of any desired struc- tural gene, for example, in the first place, a gene which is intrinsic to the host and codes for a protein which brings about transport into the periplasmic space or to a
Ce a a RE vd Tat Sot be ay i» Chi cell membrane. 1t is possible in this manner to prepare fusion proteins which can be removed from the cytoplasm, and thus be more readily isolated, and/or be protected from degradation by enzymes intrinsic to the cell. How- ever, it is also possible to generate fusion proteins which, by reason of their insolubility, can readily be separated from the proteins intrinsic to the cell. It is also possible to express the desired proteins directly by placing the structural gene immediately downstream of the start codon ATG.
Examples of polypeptides which can be obtained according to the invention are insulin, interferons, interleukins, such as interleukin-2, hirudin or somatostatin.
The invention is jliustrated in detail by the examples
Co ~which follow. Reference may be made to the textbook : "Molecular Cloning” by Maniatis et al., Cold Spring Harbor (1982), with regard to the individual process steps.
Example 1
Chromosomal E. coli DNA is cleaved with Hinf I, and the 492 bp fragment is isolated which contains, of the trp operon, the promoter, operator, the structural gene of the L-peptide, the attenuator and the codons of the trp E structural gene for the first six amino acids. This fragment is filled in with deoxynucleotide triphosphates by means of
Klenow polymerase, connected at both ends to an oligo- nucleotide which contains a recognition sequence for
Hind 111, and then cleaved with Hind III. The Hind 111 fragment thus obtained is Ligated in the Hind 111 cleavage site of pBR 322. The plasmid thus obtained is ptrpE2-1 (J.C. gdmann et al., OP. cit.). This is trans- ferred as described into the plasmid ptrpL1.
For the conversion of this starting material into a vec- oo tor according to the invention it is reacted with Cla 1
Qo . - 8 -
Co as recommended by the manufacturer (New England Biolabs).
Cr After incubation is complete the incubation mixture is extracted with phenol, the organic phase is separated off, and the DNA is precipitated by addition of 2.5 times
S the volume of ethanol and incubation at -20°C.
The DNA is removed by centrifugation and then treated with alkaline phosphatase (Boehringer Mannheim) in order to remove 5'-phosphate residues.
The synthetically prepared oligonucleotide IX 5! CGACCATGGT 3! (1X) is phosphorylated at the 5' end with the enzyme polynuc- leotide kinase and ATP. For this purpose, the synthetic oligonucleotide is heated at 70°C for 5 minutes and then immediately cooled in an ice bath. The phosphoryl- ation is carried out in 25 pl of buffer (50 mM tris.HCL, pH 7.6; 10 mM MgClp, 5S mM dithiothreitol (DTT)) with the addition of 100 pM ATP and about 10 units of Té-poly- nucleotide kinase, at 37°C over the course of 30 minutes.
The reaction is stopped by addition of the sodium salt of ethylenediaminetetraacetic acid (EDTA) to a final con- centration of 50 uM. Excess ATP can be removed by, for example, gel filtration on sepharose (SEPHADEX R G 50, oo fine).
The oligonucleotide IX is self-complementary and can associate with itself to give the double-stranded struc- ture X 5° CGACCATGGT 3 (xX)
TGGTACCAGC
- 35
This double-stranded oligonucleotide X has protruding ends which allow insertion into the Cla I site of the ‘opened plasmid ptrpL1.
CO
« . Co
About 50 ng of the oligonucleotide are incubated with about @ 1 pg of the reacted plasmid, which has been treated with * phosphatase, in 30 pl of buffer (50 mM tris. HCL, pH 7.4; 10 mM MgClp, 10 mM DTT) with the addition of 1 mM ATP and 0.1 ng/mL bovine serum albumin (BSA) at 12°C for 20 hours. The plasmid pH 131/5 is obtained (Figure 1).
The reaction mixture can be used immediately for the transformation of competent E. coli cells. Selection is carried out on agar plates using L broth (H.J. Miller,
Experiments in Molecular Genetics, Cold Spring Harbor, 1972) and 50 pg/ml ampicillin.
Since an Nco I cleavage site has been inserted in the plasmid pH 1317/5, the ampicillin-resistant colonies were tested to see whether the plasmid DNA therein contained a
Hind I1I1-Nco I fragment about 300 bp in size. More than 80% of the colonies had this fragment. Sequencing by the
Maxam-Gilbert method confirmed the incorporation of the synthetic DNA fragment and the sequence of the plasmid pH 1314/5 as indicated in Figure 1.
Example 2
The plasmid p 159/6 as shown in Figure 5 of German Offen-
Legungsschrift 3,419,995 is incubated with the enzymes
EcoR I and Sal I, as recommended by the manufacturers, and a 420 bp DNA fragment which contains the genetic information for human interleukin-2 is separated off by gel electrophoresis. The single-stranded protruding ends are degraded with mung bean nuclease (Pharmacia P-L Bio- chemicals) under the conditions recommended by the manufacturer.
The plasmid pH 131/5 is reacted with Nco 1, and the pro- truding single-stranded ends are Likewise degraded with mung bean nuclease. This is followed by incorporation of the structural gene for interlteukin-2, which is now
~ “ - . . N ‘ Co - - 10 - 265960 : blunt-ended, into the plasmid, which has been opened and 3 made blunt-ended, using DNA (igase under "blunt-end" con- ditions. This results in re-formation of the Ncol cleav- age site. Transformation into E. coli 294 is followed by selection of the ampicillin-resistant clones which have appropriate restriction fragments, for example an Eco RI-
Xba I fragment comprising about 260 bp, or an Eco RI-Sac
I fragment having about 150 bp.
The nucleotide sequence was confirmed for the plasmid pH 185/11 (Figure 2) by sequencing. The Nco I restriction site is retained in this construct.
For the expression of interleukin-2, E. coli 294 bacteria i which contain the plasmid pH 185/11 are incubated in LB medium (H.J. Miller, op. cit.) containing 50 pa/mt ampi- cillin, with aeration, overnight. Then a 1:100 dilution in
M 9 medium (H.J. Miller, op. cit.) containing 1 pa/mi thiamine and 500 pa/ml casamino acids is prepared. At an 0D of 0.5, induction can be carried out with indolyl-3- acrylic acid to a final concentration of 15 pa/mi. The bacteria are removed by centrifugation after a further 2 ' to 3 hours. It is possible by SDS gel electrophoresis to detect with the induced bacteria a strong protein band which reacts with antibodies against an interleukin-2 prepared in accordance with German Offenlegungsschrift 3,419,995. The band corresponds to the expected molecular weight of interteukin-2 and does not occur with non- induced bacteria. The biological activity of the inter- leukin-2 can be detected in high concentration in the induced bacteria.
The abovementioned conditions for culturing the bacteria apply to shaken flasks. Higher concentrations of cas- amino acids and/or L-tryptophan should be added for fermentation to higher 0D values (above 3).
pe
CQ
§ "a - 11 —-
Example 3
Q
The structural gene for human A-interferon was obtained from a cDNA bank. The clones contain the inserts in the Pst
I site of the plasmid pBR 322. A segment of 120 bp from the structural gene of B-interferon was jsolated by exposure to the restriction enzymes Hint I and Pst 1. The recog- nition sequence of the Hinf I site starts 16 nucleotides downstream of the codon for the N-terminal methionine of this biologically active B-interferon.
The oligonucleotide XI, obtained by synthesis, 5' CATGAGCTACAATCTTCTTGG 3 (XI) 3! TCGATGTTAGAAGAACCTAA 5°!
Nco 1 Hinf 1 : Po. : +s added onto the Hinf I end of the fragment using DNA
Ligase. DNA segment XII is obtained.
Moreover, a DNA segment of 365 bp was isolated from the structural gene of B-interferon using Pst I and Bgl Il.
This segment was cloned in the commercially available plasmid puUC 12 which had previously been reacted with Pst 1 and Bam HI. The plasmid pH 188 is obtained. After amplification and re-isolation, the plasmid pH 188 is in- cubated with Pst I and Eco RI, and the B-interferon gene fragment is jsolated (DNA segment XI111).
The plasmid pH 131/5 is reacted with the restriction en- zymes Nco 1 and Eco RI. This is followed by incubation of DNA segments XII and XIII with the opened plasmid in the presence of the enzyme DNA ligase, under conditions which result in covalent coupling of the Linkages. The expected sequence in the plasmid pH 192/5 is confirmed by restriction analysis and sequencing (Figure 3).
The process for the expression of the R-interferon is a . 4 RY - 12 - analogous to Example 2. Again, a pronounced band is ® detected on the electrophoresis gel after induction, this : band not being present with non-induced bacteria. The biological activity of B-interferon can be detected in the extracts from the bacteria.
The structural gene for interleukin-2 was inserted in the Nco I site of the plasmid pH 131/5 in accordance with
Example 2. After reaction of the plasmid with Eco RI, the protruding ends were made blunt-ended by incubation with Klenow polymerase in the presence of deoxyadenosine triphosphate and deoxythymidine triphosphate.
Into this plasmid which has been opened and made blunt- ended the commercially available terminator of the trp operon (Pharmacia P-L Biochemicals) is incorporated under “blunt-end” conditions with simultaneous ring-closure.
After growth and induction of the bacteria as described in Example 2 and previously, the bacteria are separated off and lysed. SDS gel electrophoresis shows no change in the band of the interleukin-2 protein, which has the same intensity as in Example 2. However, the band cor- responding to g-lactamase exhibits a markedly lower intensity.
Claims (9)
1. DNA segment of the trp operon from E. coli, which contains the sequence (coding strand) 1 5! GTATCGACC 3! (1) which is connected at the 5' end to the Shine-Dalgarno sequence AAGG, and at the 3' end to the start codon ATG.
>. DNA as claimed in claim 1, which has the sequence (coding strand) la 5° GTATCGACCATGG 3! (1a) which is connected at the 5' end to the Shine-Dalgarno sequence AAGG, and in which the G at the 3' end is the first nucleotide of a structural gene downstream of the start codon.
3. A process for the preparation of a vector having the "trp expression system of E. coli, which comprises cleavage with the restriction enzyme Nco I of an E. coli vector which contains the DNA sequence 1 (coding strand) followed by 5' ATGG 3', and, a) ligation of a gene structure of DNA sequence II 5° CATGX ... 3 (11) 3! Y ... 5° in which X and Y denote the first complementary pair of nucleotides downstream of the start codon of a structural gene, in the cleavage site, or b) enzymatic filling in of the cleavage site and lLig- ation of the DNA of the sequence 111 5! GTA TCG ACC ATG 3 (111) 3 CAT AGC TGG TAC 5! with a DNA of the sequence IV 5° X ... 3 (1v) 3! Y ... 5° in which X and Y have the abovementioned meaning, or ¢) enzymatic degradation of the protruding sequence of the cleavage site, and Ligation of the DNA of the sequence VI
Ce Po - 14 - HOE 85/F 072 5! GTA TCG AC 3 (vl) J 3 CAT AGC TG 5°! : with a DNA of the sequence VII 5! Z ATG X ... 3° (Vil) 3! Z'TAC Y ... 5! 1 and 2' denoting any desired pair of nucleotides, which can also be dispensed with.
4. A vector obtained by the process as claimed in claim 3.
5. A vector as claimed in claim 4 which is Plasmid pH 131/5 as shown in Figure 1.
6. A vector as claimed in claim 4 which is Plasmid pH 185/11 as shown in Figure 2.
7. A vector as claimed in claim 4 which is Plasmid pH 192/5 as shown in Figure 3, p
8. E. coli which contains a vector as claimed in claim 4.
9. A process for the preparation of a polypeptide composed of genetically codable amino acids, which comprises induction of expression of E. coli cells as claimed in claim 8.
g “ :
Lo . - -1 - HOE 85/F 072 Abstract of the Disclosure: 2659 0 when, in the trp operon of E. coli, the adenosine immedi- ately upstream of the ATG start codon is replaced by cytidine, and guanosine is connected downstream of the start codon ATG, then an Nco I cleavage site which permits cloning is obtained. The operon thus modified results in very strong expression of the gene downstream of the start codon. In addition, it is possible for the formation of AB -Lactamase to be increased, which results in increased ampicillin resistance, which can be utilized for selec- tion. ’
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19853514113 DE3514113A1 (en) | 1985-04-19 | 1985-04-19 | CHANGE OF THE DNA SEQUENCE BETWEEN SHINE-DALGARNO SEQUENCE AND START CODON OF THE TRP OPERON TO INCREASE PROTEIN EXPRESSION |
Publications (1)
Publication Number | Publication Date |
---|---|
PH26596A true PH26596A (en) | 1992-08-19 |
Family
ID=6268543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH33672A PH26596A (en) | 1985-04-19 | 1986-04-17 | Modification of the DNA sequence between the shine-dalgarno sequence and the start codon of the TRP operon to increase protein expression |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0198415B1 (en) |
JP (1) | JPH0665317B2 (en) |
KR (1) | KR940004543B1 (en) |
AT (1) | ATE44046T1 (en) |
AU (1) | AU600229B2 (en) |
CA (1) | CA1321963C (en) |
DE (2) | DE3514113A1 (en) |
DK (1) | DK172695B1 (en) |
ES (2) | ES8704541A1 (en) |
FI (1) | FI84362C (en) |
GR (1) | GR861022B (en) |
HU (1) | HU196458B (en) |
IE (1) | IE58994B1 (en) |
IL (1) | IL78529A (en) |
NO (1) | NO175646C (en) |
NZ (1) | NZ215858A (en) |
PH (1) | PH26596A (en) |
PT (1) | PT82417B (en) |
ZA (1) | ZA862925B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
AU8379991A (en) * | 1990-09-14 | 1992-03-26 | Astra Aktiebolag | A novel method of generating clones for the expression of unfused proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3247922A1 (en) * | 1982-12-24 | 1984-06-28 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | DNA SEQUENCES, THEIR PRODUCTION, PLASMIDES CONTAINING THESE SEQUENCES AND THE USE THEREOF FOR THE SYNTHESIS OF EUKARYOTIC GENE PRODUCTS IN PROKARYOTS |
JPS60188077A (en) * | 1984-03-09 | 1985-09-25 | Teruhiko Beppu | Novel manifestation plasmid having whole sequence of calf prochymosin cdna |
DE3430683A1 (en) * | 1984-08-21 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | SYNTHETIC REGULATION REGION |
-
1985
- 1985-04-19 DE DE19853514113 patent/DE3514113A1/en not_active Withdrawn
-
1986
- 1986-04-09 DE DE8686104879T patent/DE3663956D1/en not_active Expired
- 1986-04-09 AT AT86104879T patent/ATE44046T1/en not_active IP Right Cessation
- 1986-04-09 EP EP86104879A patent/EP0198415B1/en not_active Expired
- 1986-04-17 FI FI861624A patent/FI84362C/en not_active IP Right Cessation
- 1986-04-17 PT PT82417A patent/PT82417B/en unknown
- 1986-04-17 GR GR861022A patent/GR861022B/en unknown
- 1986-04-17 PH PH33672A patent/PH26596A/en unknown
- 1986-04-17 IL IL78529A patent/IL78529A/en not_active IP Right Cessation
- 1986-04-17 HU HU861613A patent/HU196458B/en unknown
- 1986-04-17 NZ NZ215858A patent/NZ215858A/en unknown
- 1986-04-17 ES ES554097A patent/ES8704541A1/en not_active Expired
- 1986-04-18 NO NO861551A patent/NO175646C/en unknown
- 1986-04-18 CA CA000507096A patent/CA1321963C/en not_active Expired - Lifetime
- 1986-04-18 JP JP61089832A patent/JPH0665317B2/en not_active Expired - Lifetime
- 1986-04-18 DK DK198601796A patent/DK172695B1/en not_active IP Right Cessation
- 1986-04-18 ZA ZA862925A patent/ZA862925B/en unknown
- 1986-04-18 IE IE103186A patent/IE58994B1/en not_active IP Right Cessation
- 1986-04-18 AU AU56387/86A patent/AU600229B2/en not_active Expired
- 1986-04-19 KR KR1019860003040A patent/KR940004543B1/en not_active IP Right Cessation
- 1986-06-19 ES ES556233A patent/ES8706818A1/en not_active Expired
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kaster et al. | Analysis of a bacterial hygromycin B resistance gene by transcriptional and translational fusions and by DNA sequencing | |
CA1341124C (en) | Genetic engineering process for the preparation of hirudins, and means for carrying out this process | |
Hallewell et al. | Plasmid vectors containing the tryptophan operon promoter suitable for efficient regulated expression of foreign genes | |
KR950000299B1 (en) | Fusion proteins method for their production and their use | |
EP0196864A2 (en) | Alkaline phosphatase-mediated processing and secretion of recombinant proteins, DNA sequences for use therein and cells transformed using such sequences | |
IL95495A (en) | Fusion proteins their preparation and use | |
JPH08242881A (en) | Preparation of peptide by expressing partially synthesized gene | |
JP2001525662A (en) | Method for preparing synthetic repetitive DNA | |
HU197349B (en) | Process for producing cloning vectors usable for the expression of growth hormones | |
Miki et al. | Organization of the lexA gene of Escherichia coli and nucleotide sequence of the regulatory region | |
Tsurimoto et al. | Bacteriophage lambda initiators: preparation from a strain that overproduces the O and P proteins | |
DK166681B1 (en) | DNA SEQUENCES, DNA SEQUENCES AND DNA OLIGONUCLEOTIDES FOR USE IN THE PREPARATION OF THE FIRST DNA SEQUENCES, HYBRID PLASMIDS CONTAINING DNA SEQUENCE, HOUSE CELLS WITH 2 | |
ES2281133T3 (en) | IDENTIFICATION OF HUMAN CELLULAR LINES FOR THE PRODUCTION OF HUMAN PROTEINS THROUGH THE ENDOGENA ACTIVATION OF GENES. | |
Andrews et al. | A tightly regulated high level expression vector that utilizes a thermosensitive lac repressor: production of the human T cell receptor Vβ5. 3 in Escherichia coli | |
Thomas et al. | Escherichia coli plasmid vectors containing synthetic translational initiation sequences and ribosome binding sites fused with the lacZ gene | |
NZ200145A (en) | Dna molecules coding for interferon;oligonucleotide intermediates;recombinant dna method for production of interferon;transformed microorganisms | |
CA1321963C (en) | Modification of the dna sequence between the shine-dalgarno sequence and the start codon of the trp operon to increase protein expression | |
EP0159123B1 (en) | Vectors for expressing bovine growth hormone derivatives | |
WO1988005082A1 (en) | Microbial production of peptide oligomers | |
EP0108045B1 (en) | Reca promoter dependent polypeptide production | |
CA1340280C (en) | Synthetic signal sequence for the transport of proteins in expression systems | |
IE62522B1 (en) | A process for the preparation of foreign proteins in streptomycetes | |
NO842296L (en) | NEW VECTOR | |
JPH08103278A (en) | Production of active human alt | |
Ma | Expression and purification of alpha-human atrial natriuretic peptide in Escherichia coli by fusion with Erwinia chrysanthemi L-asparaginase |